How to access Enhertu from Oman, the named-patient import pathway, 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-13.
An Omani patient with HER2-positive and HER2-low breast cancer, HER2-positive gastric cancer, HER2-mutant non-small cell lung cancer, and HER2-expressing solid tumors per the FDA tumor-agnostic indication may receive a prescription for Enhertu (trastuzumab deruxtecan) from their treating oncologist. Enhertu is FDA-approved in the United States and manufactured by Daiichi Sankyo and AstraZeneca. It is a HER2-directed antibody-drug conjugate administered by intravenous infusion. Local availability of Enhertu in Oman can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through MoH Oman remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
Ask about Enhertu in Oman
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Enhertu is a HER2-directed antibody-drug conjugate. Mechanism: a HER2-directed antibody conjugated to a topoisomerase I inhibitor (DXd) by a cleavable tetrapeptide-based linker. Dosing: 5.4 mg/kg by intravenous infusion every three weeks for breast cancer, 6.4 mg/kg for gastric cancer, per FDA labeling. Baseline workup per FDA labeling includes complete blood count with differential, liver function tests, baseline left ventricular ejection fraction, and high-resolution chest imaging for interstitial lung disease screening. The FDA boxed warning covers interstitial lung disease and embryo-fetal toxicity. Other important warnings include interstitial lung disease and pneumonitis (including fatal cases), left ventricular dysfunction, neutropenia, and embryo-fetal toxicity. Your oncologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Enhertu legally importable into Oman?
Yes, through the Oman Ministry of Health (MoH) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Oman has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The MoH Oman named-patient route allows an Omani-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.
How the pathway works, step by step
- Consultation with your treating oncologist. The prescribing decision is clinical. Your oncologist documents the indication, prior therapies where relevant, and rationale for Enhertu.
- Baseline screening. Complete blood count with differential, liver function tests, baseline left ventricular ejection fraction, and high-resolution chest imaging for interstitial lung disease screening are confirmed and documented.
- MoH Oman named-patient application. Your oncologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from Daiichi Sankyo and AstraZeneca's authorised distribution under DSCSA chain-of-custody.
- Cold-chain shipment. Enhertu requires refrigerated transport at 2 to 8 degrees Celsius. Shipments include temperature-monitored packaging with continuous loggers and tamper-evident seals.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your oncologist initiates therapy.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Enhertu as the indicated next step
- Verification of their Omani medical licence
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening consistent with FDA labeling (see above)
- The planned dosing regimen (5.4 mg/kg by intravenous infusion every three weeks for breast cancer, 6.4 mg/kg for gastric cancer, per FDA labeling)
- A monitoring plan covering ILD monitoring plan, LVEF baseline, and HER2 IHC or ISH result
Reserve Meds provides a physician documentation kit tailored for HER2-directed antibody-drug conjugate therapies, including the templates MoH Oman reviewers commonly request.
Typical costs and indicative timing
Reserve Meds gives you a transparent, itemised custom quote at intake. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, MoH Oman documentation handling, cold-chain shipping, and coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling cadence aligned to the dosing schedule.
Where Reserve Meds fits in
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Enhertu specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for MoH Oman review, including HER2-directed antibody-drug conjugate class templates.
- Cold-chain logistics. Temperature-monitored, internationally tracked shipment to your named dispensing facility with continuous temperature loggers.
- Dedicated case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating oncologist, and dispensing sits with the licensed Omani pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
Frequently asked
Is this legal in Oman? Yes, when executed through the MoH Oman named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Omani tertiary centers.
What about the boxed warning? The FDA boxed warning on Enhertu covers interstitial lung disease and embryo-fetal toxicity. Your oncologist performs the risk-benefit assessment, schedules monitoring, and counsels the patient per labeling. Reserve Meds does not make that clinical judgement, your physician does.
Will my private health insurance cover this? Cash-pay is the default posture. Cash-pay is the default posture in Oman; some private plans cover specialty imports case-by-case. We supply documentation for your submission but do not process insurance claims.
How does cold-chain affect timing? Enhertu ships refrigerated. We use validated packaging with continuous temperature monitoring, and arrival temperature data is logged on every shipment.
What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Omani tertiary centers (Sultan Qaboos University Hospital, the Royal Hospital, and Khoula Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what MoH Oman reviewers commonly ask for.
Next step
For Enhertu coordination in Oman, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Frequently asked questions
How can I get Enhertu in Oman if it is not approved or available there?
Reserve Meds coordinates US-sourced Enhertu for patients in Oman through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Oman and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Enhertu in Oman through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Enhertu. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Oman, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Enhertu in Oman through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Enhertu to a patient in Oman?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Enhertu to your treating physician or hospital pharmacy in Oman, with appropriate handling for the product.
How long does it take, and what does Enhertu in Oman cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Enhertu in Oman?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.